American Century Companies’s Zevra Therapeutics ZVRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$759K Buy
+52,903
New +$588K ﹤0.01% 2487
2024
Q2
– Sell
-18,159
Closed -$105K – 2961
2024
Q1
$105K Sell
18,159
-524
-3% -$3.22K ﹤0.01% 2857
2023
Q4
$122K Buy
18,683
+1,004
+6% +$4.7K ﹤0.01% 2789
2023
Q3
$85.2K Buy
17,679
+4,199
+31% +$21K ﹤0.01% 2745
2023
Q2
$68.7K Buy
+13,480
New +$72.6K ﹤0.01% 2736

Other funds holding ZVRA

American Century Companies's ZVRA Position: Q2 2026 in Review

American Century Companies opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 52,903 shares worth $759K. The stake represents ﹤0.01% of the portfolio and ranks #2487 among its holdings. This is a return to the name: American Century Companies previously reported a position in ZVRA as recently as Q1 2024.

American Century Companies first reported a position in ZVRA in Q2 2023 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • American Century Companies held 52,903 shares of Zevra Therapeutics worth $759K as of Q2 2026.
  • Zevra Therapeutics was a new American Century Companies position in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2487 holding.
  • American Century Companies first reported a position in Zevra Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.